pegylated human adrenomedullin (HM201)
/ Himuka AM Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 01, 2023
Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201
(clinicaltrials.gov)
- P1 | N=53 | Completed | Sponsor: Syneos Health | Recruiting ➔ Completed | Trial primary completion date: Aug 2022 ➔ Dec 2022
Trial completion • Trial primary completion date • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
April 27, 2022
Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201
(clinicaltrials.gov)
- P1 | N=68 | Recruiting | Sponsor: Syneos Health | Not yet recruiting ➔ Recruiting
Enrollment open • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
1 to 2
Of
2
Go to page
1